conducted a large-scale clinical analysis of NSCLC patients and demonstrated that those harboring ARID1A/ARID1B mutations exhibited enhanced clinical responses to immune checkpoint blockade therapy, including PD-1/PD-L1 and CTLA-4 inhibitors. This evidence concerns the gene ARID1A and non-small cell lung carcinoma.